Compare Enveric Biosciences Inc (ENVB) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Lowe`s Companies Inc — how do they compare? Enveric Biosciences Inc trades at $1.38 (market cap $5.32M), while Lowe`s Companies Inc trades at $214.26 (market cap $117.56B). The key difference: Lowe`s Companies Inc is far larger — about 22097.7× Enveric Biosciences Inc's market cap, and Lowe`s Companies Inc pays a 2.38% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | LOW | |
|---|---|---|
Market Cap | $5.32M | $117.56B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $287.39 |
52-Week Low | $1.28 | $206.62 |
Enterprise Value | $408.82K | $159.31B |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
Lowe's Companies (LOW) trades at $213.81, up 2.94% on the day, with a bearish technical signal but strong analyst consensus. Recent earnings beats and a 7.51% net income margin highlight operational strength, though revenue has declined from $96.2B in 2022 to $83.7B in 2025. The stock shows support near $205 and resistance at $215, with a consensus price target of $260.88 implying 22% upside. Dividend growth remains a key attraction, with the quarterly payout rising to $1.25.
LOW offers value with a P/E of 17.72 and bullish analyst sentiment (60.79% buy ratings), but faces risks from high debt levels and competitive pressures. The outlook hinges on execution in the professional segment and interest rate sensitivity, with near-term volatility expected around Q2 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
